US tariffs threaten India's pharmaceutical exports, risking higher drug costs and supply disruptions in the US.

Indian pharmaceutical companies fear US tariffs could raise costs and disrupt their exports, which supply nearly half of US generic drugs. The industry, third-largest globally, aims for $130 billion growth by 2030, needing budget support for R&D and simpler regulations. India's drugs saved the US $219 billion in 2022, with potential for stronger US-India health security ties to diversify pharmaceutical supply chains and boost manufacturing.

2 months ago
8 Articles